Northeast Tiger Pharmaceutical : Announcements and Notices - ANNOUNCEMENT UPDATE ON THE POSSIBLE TRANSACTION PURSUANT TO RULE 3.7 OF THE TAKEOVERS CODE

1677c47b-7de1-4df5-bbc2-daaa206db4cc.pdf

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

東北虎藥業股份有限公司

NORTHEAST TIGER PHARMACEUTICAL CO., LTD.*

(A joint stock limited company established in the People's Republic of China)

(Stock Code: 8197)

ANNOUNCEMENT UPDATE

ON THE POSSIBLE TRANSACTION PURSUANT TO RULE 3.7 OF THE TAKEOVERS CODE

This announcement is made by Northeast Tiger Pharmaceutical Co., Ltd.* (the "Company") pursuant to Rule 3.7 of the Takeovers Code.

Reference is made to the announcements of the Company dated 15 December 2015 and 14 January 2016 in relation to the MOU entered into between the Vendors and the Potential Purchaser regarding the Possible Transaction (the "Announcements"). Unless otherwise specified, terms defined in the Announcements shall have the same meanings when used in this announcement.

The Board wishes to update its shareholders and potential investors that, as informed by the Vendors on 29 January 2016, the Vendors and the Potential Purchaser entered into an extension letter (the "Extension Letter") in respect of the MOU. Pursuant to the Extension Letter, the Vendors and the Potential Purchaser agreed to extend the relevant expiry date for the entering into of the Definitive Agreement from 31 January 2016 to 5 February 2016.

Save for the above extension of the relevant expiry date as effected by the Extension Letter, all the legally binding provisions of the MOU shall remain in full force and effect. Other than the MOU (some of which terms are legally binding as stated in the Announcements) as mentioned in the Announcements, no formal or legally binding agreement has been entered into between the Vendors and the Potential Purchaser.

Further announcement(s) setting out the progress of the Possible Transaction will be made as and when necessary in accordance with the Listing Rules and the Takeovers Code and on a monthly basis until an announcement of a firm intention to make an offer under Rule 3.5 of the Takeovers Code or of a decision not to proceed with the Possible Transaction is made.

WARNINGS: Shareholders and potential investors of the Company shall be aware that the completion of the Possible Transaction is subject to entering into of the Definitive Agreement and the satisfaction (or waiver as applicable) of such conditions precedent as may be specified therein; there is no assurance that the Possible Transaction will materialize. The Possible Transaction may or may not proceed, and the terms of the Possible Transaction are subject to negotiation between the Vendors and the Potential Purchaser. As such, the discussions may or may not lead to the Possible Transaction taking place. Shareholders and potential investors are urged to exercise extreme caution when dealing in the H Shares.

By Order of the Board

Northeast Tiger Pharmaceutical Co., Ltd.*

Wang Shaoyan Chairman

Jilin, People's Republic of China, 29 January 2016

As at the date of this announcement, the Company's executive directors are Wang Shaoyan, Cui Bingyan and Qin Haibo; the Company's non-executive directors are Guo Aiqun, and Zhang Jinlong and the Company's Independent non-executive directors are Chen Youfang, Zhao Zhen Xing and Hui Lai Yam.

This announcement, for which the directors of Northeast Tiger Pharmaceutical Co., Ltd.* collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to Northeast Tiger Pharmaceutical Co., Ltd.* The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the

information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this document misleading. This announcement will remain on the "Latest Company Announcement" page of the GEM website (www.hkgem.com) for at least 7 days from its date of publication and on the website of the Company (www.northeasttiger.com).

The directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquires, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.

* for identification purposes only